` HAE (Haemonetics Corp) vs S&P 500 Comparison - Alpha Spread

HAE
vs
S&P 500

Over the past 12 months, HAE has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's 24% growth.

Stocks Performance
HAE vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
HAE vs S&P 500

Loading
HAE
S&P 500
Difference

Performance By Year
HAE vs S&P 500

Loading
HAE
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Haemonetics Corp vs Peers

S&P 500
HAE
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Haemonetics Corp
Glance View

Market Cap
3.9B USD
Industry
Health Care

In the realm of healthcare, Haemonetics Corp. operates as a pivotal player, bridging the gap between innovation and life-saving technology. Founded in 1971, the company has evolved to become a leader in blood management solutions, riding the wave of advanced medical technology to cater primarily to hospitals and blood collection centers. At its core, Haemonetics specializes in products and software designed to optimize the collection, processing, and surgical use of blood. Among its notable contributions are devices for blood component separation and coagulation management systems, which play a critical role in ensuring that patients around the world receive safe and effective blood therapy. Revenue streams for Haemonetics come from a diverse range of blood management systems and services. Their offerings are not limited to physical products; the company also provides comprehensive software solutions that help institutions maximize efficiencies and improve patient outcomes. With a keen focus on research and development, Haemonetics continuously innovates to meet the stringent demands of the modern healthcare landscape. Their business model thrives on a combination of direct sales, strategic partnerships, and service agreements with hospitals and blood banks, all while maintaining a strong commitment to quality and regulatory compliance. Through its strategic approach, Haemonetics not only fulfills an essential healthcare need but also crafts a sustainable financial pathway by redefining how blood and related products are managed globally.

HAE Intrinsic Value
95.86 USD
Undervaluation 19%
Intrinsic Value
Price
Back to Top